CytoDyn Inc. (CYDY) - Publications https://www.cytodyn.com/publications The latest news released by CytoDyn Inc. en-us Equisolve https://d1io3yog0oux5.cloudfront.net/_4a5da93e1fbda642525e309217493120/cytodyn/logo.png CytoDyn Inc. https://www.cytodyn.com 88 31 CytoDyn’s AACR IO Poster (February 2026) https://www.cytodyn.com/publications/detail/3831/cytodyns-aacr-io-poster-february-2026 Thu, 19 Feb 2026 00:00:00 -0500 https://www.cytodyn.com/publications/detail/3831/cytodyns-aacr-io-poster-february-2026 CytoDyn’s SABCS Poster (2025) https://www.cytodyn.com/publications/detail/3829/cytodyns-sabcs-poster-2025 Fri, 12 Dec 2025 00:00:00 -0500 https://www.cytodyn.com/publications/detail/3829/cytodyns-sabcs-poster-2025 A Proof-of-Concept Phase 2a Partly Randomised Study Evaluating Leronlimab in Patients With Presumed Non-Cirrhotic Metabolic Dysfunction–Associated Steatohepatitis https://onlinelibrary.wiley.com/doi/10.1002/lci2.70028 Tue, 14 Oct 2025 00:00:00 -0400 https://onlinelibrary.wiley.com/doi/10.1002/lci2.70028 CytoDyn’s ESMO GI Poster (2025) https://www.cytodyn.com/publications/detail/3793/cytodyns-esmo-gi-poster-2025 Fri, 04 Jul 2025 00:00:00 -0400 https://www.cytodyn.com/publications/detail/3793/cytodyns-esmo-gi-poster-2025 CytoDyn’s ESMO Breast Cancer Poster (2025) https://www.cytodyn.com/publications/detail/3777/cytodyns-esmo-breast-cancer-poster-2025 Thu, 15 May 2025 00:00:00 -0400 https://www.cytodyn.com/publications/detail/3777/cytodyns-esmo-breast-cancer-poster-2025 Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): a Randomized, Double-Blind, Placebo-Controlled Trial https://journals.lww.com/jaids/abstract/9900/leronlimab_treatment_for_multidrug_resistant_hiv_1.602.aspx Thu, 20 Feb 2025 00:00:00 -0500 https://journals.lww.com/jaids/abstract/9900/leronlimab_treatment_for_multidrug_resistant_hiv_1.602.aspx FcRn-enhancing mutations lead to increased and prolonged levels of the HIV CCR5-blocking monoclonal antibody leronlimab in the fetuses and newborns of pregnant rhesus macaques https://www.tandfonline.com/doi/full/10.1080/19420862.2024.2406788 Thu, 26 Sep 2024 00:00:00 -0400 https://www.tandfonline.com/doi/full/10.1080/19420862.2024.2406788 CCR5 and CCL5 in metastatic colorectal cancer https://www.cytodyn.com/publications/detail/3501/ccr5-and-ccl5-in-metastatic-colorectal-cancer Mon, 22 Jul 2024 00:00:00 -0400 https://www.cytodyn.com/publications/detail/3501/ccr5-and-ccl5-in-metastatic-colorectal-cancer Understanding immune dysregulation in post- acute sequelae of COVID-19 (PASC)—The hunt for effective treatments https://www.cytodyn.com/publications/detail/3498/understanding-immune-dysregulation-in-post--acute-sequelae-of-covid-19-pascthe-hunt-for-effective-treatments Thu, 09 May 2024 00:00:00 -0400 https://www.cytodyn.com/publications/detail/3498/understanding-immune-dysregulation-in-post--acute-sequelae-of-covid-19-pascthe-hunt-for-effective-treatments Infectious Diseases Society of America: Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome https://www.cytodyn.com/publications/detail/3394/infectious-diseases-society-of-america-reduced-cell-surface-levels-of-c-c-chemokine-receptor-5-and-immunosuppression-in-long-coronavirus-disease-2019-syndrome Fri, 22 Apr 2022 00:00:00 -0400 https://www.cytodyn.com/publications/detail/3394/infectious-diseases-society-of-america-reduced-cell-surface-levels-of-c-c-chemokine-receptor-5-and-immunosuppression-in-long-coronavirus-disease-2019-syndrome PLOS Pathogens: Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species https://www.cytodyn.com/publications/detail/3391/plos-pathogens-suppression-of-human-and-simian-immunodeficiency-virus-replication-with-the-ccr5-specific-antibody-leronlimab-in-two-species Thu, 31 Mar 2022 00:00:00 -0400 https://www.cytodyn.com/publications/detail/3391/plos-pathogens-suppression-of-human-and-simian-immunodeficiency-virus-replication-with-the-ccr5-specific-antibody-leronlimab-in-two-species Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects https://www.cytodyn.com/publications/detail/3410/leronlimab-pro-140-in-vitro-activity-against-4-class-drug-resistant-hiv-1-from-heavily-treatment-experienced-subjects Mon, 28 Feb 2022 00:00:00 -0500 https://www.cytodyn.com/publications/detail/3410/leronlimab-pro-140-in-vitro-activity-against-4-class-drug-resistant-hiv-1-from-heavily-treatment-experienced-subjects Frontiers in Immunology: CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab https://www.cytodyn.com/publications/detail/3383/frontiers-in-immunology-ccr5-receptor-occupancy-analysis-reveals-increased-peripheral-blood-ccr5-cd4-t-cells-following-treatment-with-the-anti-ccr5-antibody-leronlimab Fri, 19 Nov 2021 00:00:00 -0500 https://www.cytodyn.com/publications/detail/3383/frontiers-in-immunology-ccr5-receptor-occupancy-analysis-reveals-increased-peripheral-blood-ccr5-cd4-t-cells-following-treatment-with-the-anti-ccr5-antibody-leronlimab Nature Communications: Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission https://www.cytodyn.com/publications/detail/3382/nature-communications-antibody-based-ccr5-blockade-protects-macaques-from-mucosal-shiv-transmission Mon, 07 Jun 2021 00:00:00 -0400 https://www.cytodyn.com/publications/detail/3382/nature-communications-antibody-based-ccr5-blockade-protects-macaques-from-mucosal-shiv-transmission Journal of Translational Autoimmunity: Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab https://www.cytodyn.com/publications/detail/3380/journal-of-translational-autoimmunity-case-study-of-a-critically-ill-person-with-covid-19-on-ecmo-successfully-treated-with-leronlimab Tue, 16 Mar 2021 00:00:00 -0400 https://www.cytodyn.com/publications/detail/3380/journal-of-translational-autoimmunity-case-study-of-a-critically-ill-person-with-covid-19-on-ecmo-successfully-treated-with-leronlimab Springer Nature: Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy https://www.cytodyn.com/publications/detail/3379/springer-nature-leronlimab-a-humanized-monoclonal-antibody-to-ccr5-blocks-breast-cancer-cellular-metastasis-and-enhances-cell-death-induced-by-dna-damaging-chemotherapy Sat, 23 Jan 2021 00:00:00 -0500 https://www.cytodyn.com/publications/detail/3379/springer-nature-leronlimab-a-humanized-monoclonal-antibody-to-ccr5-blocks-breast-cancer-cellular-metastasis-and-enhances-cell-death-induced-by-dna-damaging-chemotherapy Journal of Translational Autoimmunity: Disruption of CCR5 Signaling to Treat COVID-19-Associated Cytokine Storm: Case Series of Four Critically Ill Patients Treated with Leronlimab https://reader.elsevier.com/reader/sd/pii/S2589909021000034?token=B59F0D3236F9B631A64F5A33EB55ED3A1A935DA29C19D8B641A38BB58FFE8B7977FE396F56BA020B3D0483A64438E592&originRegion=us-east-1&originCreation=20220405181748 Wed, 30 Dec 2020 00:00:00 -0500 https://reader.elsevier.com/reader/sd/pii/S2589909021000034?token=B59F0D3236F9B631A64F5A33EB55ED3A1A935DA29C19D8B641A38BB58FFE8B7977FE396F56BA020B3D0483A64438E592&originRegion=us-east-1&originCreation=20220405181748 International Journal of Infectious Diseases: CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14 https://www.cytodyn.com/publications/detail/3378/international-journal-of-infectious-diseases-ccr5-inhibition-in-critical-covid-19-patients-decreases-inflammatory-cytokines-increases-cd8-t-cells-and-decreases-sars-cov2-rna-in-plasma-by-day-14 Fri, 30 Oct 2020 00:00:00 -0400 https://www.cytodyn.com/publications/detail/3378/international-journal-of-infectious-diseases-ccr5-inhibition-in-critical-covid-19-patients-decreases-inflammatory-cytokines-increases-cd8-t-cells-and-decreases-sars-cov2-rna-in-plasma-by-day-14 Infectious Diseases Society of America: Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab https://www.cytodyn.com/publications/detail/3377/infectious-diseases-society-of-america-clinical-characteristics-and-outcomes-of-coronavirus-disease-2019-patients-who-received-compassionate-use-leronlimab Tue, 20 Oct 2020 00:00:00 -0400 https://www.cytodyn.com/publications/detail/3377/infectious-diseases-society-of-america-clinical-characteristics-and-outcomes-of-coronavirus-disease-2019-patients-who-received-compassionate-use-leronlimab National Library of Medicine: PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry null Mice https://pubmed.ncbi.nlm.nih.gov/29128556/ Sat, 24 Feb 2018 00:00:00 -0500 https://pubmed.ncbi.nlm.nih.gov/29128556/ Antimicrobial Agents and Chemotherapy: Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults https://www.cytodyn.com/publications/detail/3375/antimicrobial-agents-and-chemotherapy-phase-2a-study-of-the-ccr5-monoclonal-antibody-pro-140-administered-intravenously-to-hiv-infected-adults Tue, 20 Jul 2010 00:00:00 -0400 https://www.cytodyn.com/publications/detail/3375/antimicrobial-agents-and-chemotherapy-phase-2a-study-of-the-ccr5-monoclonal-antibody-pro-140-administered-intravenously-to-hiv-infected-adults